HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent.

Abstract
The overexpression of neuropeptide receptors observed in many cancers provides an attractive target for tumor imaging and therapy. Bombesin is a peptide exhibiting a high affinity for the gastrin releasing peptide (GRP) receptor, which is overexpressed by a variety of tumors such as breast or prostate cancer. In the present study, we have evaluated if the bombesin analogue [N(alpha)-histidinyl acetate]bombesin(7-14), radiolabeled with the novel [99mTc(OH(2))(3)(CO)(3)]+, has the potential to be used as a diagnostic radiopharmaceutical. Receptor saturation studies, carried out on the GRP receptor-expressing PC-3 human prostate cancer cell line, revealed for [99mTc(CO)(3)-N(alpha)-histidinyl acetate]bombesin(7-14) K(d) values in the subnanomolar range. Competitive binding assays, using the cold rhenium(I)-labeled analogue as a surrogate for the 99mTc-conjugate, also showed high affinity binding. Incubation of the radioconjugate with PC-3 cells resulted in a rapid temperature- and time-dependent specific internalization. At 37 degrees C more than 70% was internalized within the first 15 min and remained constant up to 2 h. Despite the weak proteolytic stability of [99mTc(CO)(3)-N(alpha)-histidinyl acetate]bombesin(7-14) in vitro, biodistribution studies, performed in PC-3 tumor-bearing mice, showed low uptake in the tumor (0.89 +/- 0.27% ID/g 30 min pi) but high uptake into the pancreas (7.11 +/- 3.93% ID/g 30 min pi), a GRP receptor-positive organ. Blockade experiment (coinjection of 300 microg bombesin/mouse with the radioligand) showed specificity of the uptake. Despite the low tumor uptake, tumor-to-blood ratios of 2.0 and 2.7 and tumor-to-muscle ratios of 8.9 and 8.0 were obtained at 30 min and 1.5 h postinjection, respectively. The promising results merit the future in vivo investigation of 99mTc/188Re-tricarbonyl-labeled bombesin analogues.
AuthorsR La Bella, E Garcia-Garayoa, M Bahler, P Bläuenstein, R Schibli, P Conrath, D Tourwé, P A Schubiger
JournalBioconjugate chemistry (Bioconjug Chem) 2002 May-Jun Vol. 13 Issue 3 Pg. 599-604 ISSN: 1043-1802 [Print] United States
PMID12009951 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Chelating Agents
  • Contrast Media
  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • Receptors, Bombesin
  • Bombesin
Topics
  • Animals
  • Binding, Competitive
  • Bombesin (analogs & derivatives, pharmacokinetics)
  • Chelating Agents
  • Contrast Media
  • Female
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Neoplasms, Experimental (diagnostic imaging, metabolism)
  • Organotechnetium Compounds
  • Radioligand Assay (methods)
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Receptors, Bombesin (antagonists & inhibitors, metabolism)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: